{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T01:51:13Z","timestamp":1794448273921,"version":"4.9.1"},"publisher-location":"Totowa, NJ","reference-count":98,"publisher":"Humana Press","isbn-type":[{"value":"9781617371431","type":"print"},{"value":"9781592598175","type":"electronic"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004]]},"DOI":"10.1007\/978-1-59259-817-5_12","type":"book-chapter","created":{"date-parts":[[2013,6,8]],"date-time":"2013-06-08T00:19:45Z","timestamp":1370650785000},"page":"223-249","source":"Crossref","is-referenced-by-count":0,"title":["Remission Maintenance in Multiple Myeloma"],"prefix":"10.1007","author":[{"given":"Heinz","family":"Ludwig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Zojer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"12_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S0140-6736(80)92941-4","volume":"2","author":"BG Durie","year":"1980","unstructured":"Durie BG, Russell DH, Salmon SE. Reappraisal of plateau phase in myeloma. Lancet 1980; 2:65\u201368.","journal-title":"Lancet"},{"key":"12_CR2","first-page":"339","volume":"4","author":"R Bataille","year":"1984","unstructured":"Bataille R, Souteyrand P, Sany J. Clinical evaluation of response or escape to chemotherapy and of survival of patients with multiple myeloma: a prospective study of 202 patients (1975\u20131982). Anticancer Res 1984; 4:339\u2013345.","journal-title":"Anticancer Res"},{"key":"12_CR3","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/j.1600-0609.1996.tb01371.x","volume":"57","author":"TM Oivanen","year":"1996","unstructured":"Oivanen TM. Prognostic value of serum M-protein doubling time at escape from plateau of multiple myeloma. The Finnish Leukaemia Group. Eur J Haematol 1996; 57:247\u2013253.","journal-title":"Eur J Haematol"},{"key":"12_CR4","first-page":"336","volume":"84","author":"A Corso","year":"1999","unstructured":"Corso A, Nozza A, Lazzarino M, et al. Plateau phase in multiple myeloma: an end-point of conventional-dose chemotherapy. Haematologica 1999; 84:336\u2013341.","journal-title":"Haematologica"},{"key":"12_CR5","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S0889-8588(05)70419-6","volume":"11","author":"M Attal","year":"1997","unstructured":"Attal M, Harousseau JL. Standard therapy versus autologous transplantation in multiple myeloma. Hematol Oncol Clin North Am 1997; 11:133\u2013146.","journal-title":"Hematol Oncol Clin North Am"},{"key":"12_CR6","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/sj.bmt.1701634","volume":"23","author":"S Kulkarni","year":"1999","unstructured":"Kulkarni S, Powles RL, Treleaven JG, et al. Impact of previous high-dose therapy on outcome after allografting for multiple myeloma. Bone Marrow Transplant 1999; 23:675\u2013680.","journal-title":"Bone Marrow Transplant"},{"key":"12_CR7","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/archinte.1975.00330010149019","volume":"135","author":"Southwest Oncology Group Study","year":"1975","unstructured":"Southwest Oncology Group Study. Remission maintenance for multiple myeloma. Arch Intern Med 1975; 135:147\u2013152.","journal-title":"Arch Intern Med"},{"key":"12_CR8","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1182\/blood.V51.6.1005.1005","volume":"51","author":"R Alexanian","year":"1978","unstructured":"Alexanian R, Gehan E, Haut A, Saiki J, Weick J. Unmaintained remissions in multiple myeloma. Blood 1978; 51:1005\u20131011.","journal-title":"Blood"},{"key":"12_CR9","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/0277-5379(93)90002-M","volume":"19","author":"A Paccagnella","year":"1983","unstructured":"Paccagnella A, Cartei G, Fosser V, et al. Treatment of multiple myeloma with M-2 protocol and without maintenance therapy. Eur J Cancer Clin Oncol 1983; 19:1345\u20131351.","journal-title":"Eur J Cancer Clin Oncol"},{"key":"12_CR10","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/bjc.1985.171","volume":"52","author":"IC MacLennan","year":"1985","unstructured":"MacLennan IC, Cusick J. Objective evaluation of the role of vincristine in induction and maintenance therapy for myelomatosis. Medical Research Council Working Party on Leukaemia in Adults. Br J Cancer 1985; 52:153\u2013158.","journal-title":"Br J Cancer"},{"key":"12_CR11","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1200\/JCO.1986.4.6.888","volume":"4","author":"HJ Cohen","year":"1986","unstructured":"Cohen HJ, Bartolucci AA, Forman WB, Silberman HR. Consolidation and maintenance therapy in multiple myeloma: randomized comparison of a new approach to therapy after initial response to treatment. J Clin Oncol 1986; 4:888\u2013899.","journal-title":"J Clin Oncol"},{"key":"12_CR12","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/bjc.1988.17","volume":"57","author":"A Belch","year":"1988","unstructured":"Belch A, Shelley W, Bergsagel D, et al. A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients. Br J Cancer 1988; 57:94\u201399.","journal-title":"Br J Cancer"},{"key":"12_CR13","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1038\/bjc.1994.474","volume":"70","author":"A Riccardi","year":"1994","unstructured":"Riccardi A, Ucci G, Luoni R, et al. Treatment of multiple myeloma according to the extension of the disease: a prospective, randomised study comparing a less with a more aggressive cystostatic policy. Cooperative Group of Study and Treatment of Multiple Myeloma. Br J Cancer 1994;70:1203\u20131210.","journal-title":"Br J Cancer"},{"key":"12_CR14","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1159\/000216479","volume":"11","author":"D Peest","year":"1988","unstructured":"Peest D, Deicher H. Induktions- und Erhaltungstherapie beim multiplen Myelom: Ergebnisse einer multizentrischen Studie, Onkologie 1988; 11:39\u201343.","journal-title":"Onkologie"},{"issue":"l","key":"12_CR15","first-page":"337","volume":"76","author":"B Barlogie Jr","year":"2003","unstructured":"Barlogie B Jr, Shaughnessy JD. Early results of total therapy II in multiple myeloma: implication of cytogenetics and FISH. Int J Hematol. 2003; 76(suppl l):337\u2013339.","journal-title":"Int J Hematol"},{"key":"12_CR16","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1111\/j.1365-2141.1994.tb04821.x","volume":"86","author":"A Palumbo","year":"1994","unstructured":"Palumbo A, Battaglio S, Napoli P, et al. Recombinant interferon-gamma inhibits the in vitro proliferation of human myeloma cells. Br J Haematol 1994; 86:726\u2013732.","journal-title":"Br J Haematol"},{"key":"12_CR17","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1016\/0277-5379(83)90095-0","volume":"19","author":"CU Ludwig","year":"1983","unstructured":"Ludwig CU, Durie BG, Salmon SE, Moon TE. Tumor growth stimulation in vitro by interferons. Eur J Cancer Clin Oncol 1983; 19:1625\u20131632.","journal-title":"Eur J Cancer Clin Oncol"},{"key":"12_CR18","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1042\/bj3090175","volume":"309","author":"JC Anthes","year":"1995","unstructured":"Anthes JC, Zhan Z, Gilchrest H, Egan RW, Siegel MI, Billah MM. Interferon-alpha down-regulates the interleukin-6 receptor in a human multiple myeloma cell line, U266. Biochem J 1995; 309:175\u2013180.","journal-title":"Biochem J"},{"key":"12_CR19","doi-asserted-by":"crossref","first-page":"4402","DOI":"10.4049\/jimmunol.147.12.4402","volume":"147","author":"M Jourdan","year":"1991","unstructured":"Jourdan M, Zhang XG, Portier M, Boiron JM, Bataille R, Klein B. IFN-alpha induces autocrine production of IL-6 in myeloma cell lines. J Immunol 1991; 147:4402\u20134407.","journal-title":"J Immunol"},{"key":"12_CR20","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1002\/eji.1830261244","volume":"26","author":"A Egle","year":"1996","unstructured":"Egle A, Villunger A, Kos M, et al. Modulation of Apo-1\/Fas (CD95)-induced programmed cell death in myeloma cells by interferon-alpha 2. Eur J Immunol 1996; 26:3119\u20133126.","journal-title":"Eur J Immunol"},{"key":"12_CR21","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1182\/blood.V92.8.2914","volume":"92","author":"H Spets","year":"1998","unstructured":"Spets H, Georgii-Hemming P, Siljason J, Nilsson K, Jernberg-Wiklund H. Fas\/APO-1 (CD95)-mediated apoptosis is activated by interferon-gamma and interferon- in interleukin-6 (IL-6)-dependent and IL-6-independent multiple myeloma cell lines. Blood 1998; 92:2914\u20132923.","journal-title":"Blood"},{"issue":"1","key":"12_CR22","first-page":"29","volume":"4","author":"K Nilson","year":"2003","unstructured":"Nilson K. The regulation of Fas induced apoptosis in multiple myeloma. 9th International Myeloma Workshop, Salamanca, May 23\u201327, 2003 Hematology J 4 (suppl 1):S29: P3.5.","journal-title":"Hematology J"},{"key":"12_CR23","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/sj.leu.2401334","volume":"13","author":"P Liu","year":"1999","unstructured":"Liu P, Oken M, Van Ness B. Interferon-alpha protects myeloma cell lines from dexametha-sone-induced apoptosis. Leukemia 1999; 13:473\u2013480.","journal-title":"Leukemia"},{"key":"12_CR24","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1046\/j.1365-2141.1998.01000.x","volume":"103","author":"T Otsuki","year":"1998","unstructured":"Otsuki T, Yamada O, Sakaguchi H, et al. Human myeloma cell apoptosis induced by interferon-alpha. Br J Haematol 1998; 103:518\u2013529.","journal-title":"Br J Haematol"},{"key":"12_CR25","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.4049\/jimmunol.161.4.2011","volume":"161","author":"P Hermann","year":"1998","unstructured":"Hermann P, Rubio M, Nakajima T, Delespesse G, Sarfati M. IFN-alpha priming of human monocytes differentially regulates gram-positive and gram-negative bacteria-induced IL-10 release and selectively enhances IL-12p70, CD80, and MHC class I expression. J Immunol 1998; 161:2011\u20132018.","journal-title":"J Immunol"},{"key":"12_CR26","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/ijc.2910220407","volume":"22","author":"S Einhorn","year":"1978","unstructured":"Einhorn S, Blomgren H, Strander H. Interferon and spontaneous cytotoxicity in man. I. Enhancement of the spontaneous cytotoxicity of peripheral lymphocytes by human leukocyte interferon. Int J Cancer 1978; 22:405\u2013412.","journal-title":"Int J Cancer"},{"key":"12_CR27","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/j.1875-9114.1997.tb03706.x","volume":"17","author":"PD Hall","year":"1997","unstructured":"Hall PD, Self SE, Hall RK. The interaction of maintenance interferon with cytolytic cells in patients with multiple myeloma who responded to cytotoxic chemotherapy. Pharmacotherapy 1997; 17:248\u2013255.","journal-title":"Pharmacotherapy"},{"key":"12_CR28","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.4049\/jimmunol.161.4.1947","volume":"161","author":"T Luft","year":"1998","unstructured":"Luft T, Pang KC, Thomas E, et al. Type I IFNs enhance the terminal differentiation of dendritic cells. J Immunol 1998; 161:1947\u20131953.","journal-title":"J Immunol"},{"issue":"l","key":"12_CR29","first-page":"23","volume":"25","author":"JL Taylor","year":"1998","unstructured":"Taylor JL, Grossberg SE. The effects of interferon -alpha on the production and action of other cytokines. Semin Oncol 1998; 25(suppl l):23\u201329.","journal-title":"Semin Oncol"},{"key":"12_CR30","first-page":"5155","volume":"47","author":"YA Sidky","year":"1987","unstructured":"Sidky YA, Borden EC. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res 1987; 47:5155\u20135161.","journal-title":"Cancer Res"},{"key":"12_CR31","first-page":"697","volume":"2","author":"H Mellstedt","year":"1979","unstructured":"Mellstedt H, Aahre A, Bjorkholm M, et al. Interferon therapy in myelomatosis. Lancet 1979; 2:697.","journal-title":"Lancet"},{"key":"12_CR32","first-page":"1331","volume":"68","author":"A Ahre","year":"1984","unstructured":"Ahre A, Bjorkholm M, Mellstedt H, et al. Human leukocyte interferon and intermittent high-dose melphalan-prednisone administration in the treatment of multiple myeloma: a randomized clinical trial from the Myeloma Group of Central Sweden. Cancer Treat Rep 1984; 68:1331\u20131338.","journal-title":"Cancer Treat Rep"},{"key":"12_CR33","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/0277-5379(86)90015-5","volume":"22","author":"H Ludwig","year":"1986","unstructured":"Ludwig H, Cortelezzi A, Scheithauer W, et al. Recombinant interferon alfa-2C versus polychemotherapy (VMCP) for treatment of multiple myeloma: a prospective randomized trial. Eur J Cancer Clin Oncol 1986; 22:1111\u20131116.","journal-title":"Eur J Cancer Clin Oncol"},{"key":"12_CR34","doi-asserted-by":"publisher","first-page":"11799","DOI":"10.1074\/jbc.273.19.11799","volume":"273","author":"T Arora","year":"1998","unstructured":"Arora T, Jelinek DF. Differential myeloma cell responsiveness to interferon -alpha correlates with differential induction of pl9(INK4d) and cyclin D2 expression. J Biol Chem 1998; 273:11799\u201311805.","journal-title":"J Biol Chem"},{"key":"12_CR35","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJM199005173222005","volume":"322","author":"F Mandelli","year":"1990","unstructured":"Mandelli F, Avvisati G, Amadori S, et al Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med 1990; 322:1430\u20131434.","journal-title":"N Engl J Med"},{"key":"12_CR36","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1182\/blood.V92.6.2184","volume":"92","author":"A Pulsoni","year":"1998","unstructured":"Pulsoni A, Avvisati G, Teresa Petrucci M, et al. The Italian experience on interferon as maintenance treatment in multiple myeloma: ten years after [letter]. Blood 1998; 92: 2184\u20132186.","journal-title":"Blood"},{"key":"12_CR37","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/j.1365-2141.1995.tb08364.x","volume":"89","author":"J Westin","year":"1995","unstructured":"Westin J, Rodjer S, Turesson I, Cortelezzi A, Hjorth M, Zador G. Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study. Cooperative Study Group. Br J Haematol 1995; 89:561\u2013568.","journal-title":"Br J Haematol"},{"key":"12_CR38","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/oxfordjournals.annonc.a059217","volume":"6","author":"H Ludwig","year":"1995","unstructured":"Ludwig H, Cohen AM, Polliack A, et al. Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies. Ann Oncol 1995; 6:467\u2013476.","journal-title":"Ann Oncol"},{"key":"12_CR39","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1200\/JCO.1995.13.9.2354","volume":"13","author":"GP Browman","year":"1995","unstructured":"Browman GP, Bergsagel D, Sicheri D, et al. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1995; 13:2354\u20132360.","journal-title":"J Clin Oncol"},{"key":"12_CR40","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/sj.leu.2401039","volume":"12","author":"J Blade","year":"1998","unstructured":"Blade J, San Miguel JF, Escudero ML, et al. Maintenance treatment with interferon alfa-2b in multiple myeloma: a prospective randomized study from PETHEMA (Program for the Study and Treatment of Hematological Malignancies, Spanish Society of Hematology). Leukemia 1998; 12:1144\u20131148.","journal-title":"Leukemia"},{"key":"12_CR41","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1046\/j.1365-2141.1998.00648.x","volume":"101","author":"MT Drayson","year":"1998","unstructured":"Drayson MT, Chapman CE, Dunn JA, Olujohungbe AB, Maclennan IC. MRC trial of alpha2b-interferon maintenance therapy in first plateau phase of multiple myeloma. MRC Working Party on Leukaemia in Adults. Br J Haematol 1998; 101:195\u2013202.","journal-title":"Br J Haematol"},{"key":"12_CR42","volume-title":"Interferon maintenance therapy in multiple myeloma patients achieving plateau phase after induction therapy: a multicenter randomized trial","author":"B Grosbois","year":"1997","unstructured":"Grosbois B, Mary JY, Michaux JL, et al. Interferon maintenance therapy in multiple myeloma patients achieving plateau phase after induction therapy: a multicenter randomized trial. VI International Workshop on Multiple Myeloma, Boston, MA, June 14\u201318, 1997."},{"key":"12_CR43","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1200\/JCO.1994.12.11.2405","volume":"12","author":"SE Salmon","year":"1994","unstructured":"Salmon SE, Crowley JJ, Grogan TM, Finley P, Pugh RP, Barlogie B. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study. J Clin Oncol 1994; 12:2405\u20132414.","journal-title":"J Clin Oncol"},{"key":"12_CR44","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/0959-8049(94)00452-B","volume":"31A","author":"D Peest","year":"1995","unstructured":"Peest D, Deicher H, Coldewey R, et al. A comparison of polychemotherapy and melphalan\/ prednisone for primary remission induction, and interferon -alpha for maintenance treatment, in multiple myeloma: a prospective trial of the German Myeloma Treatment Group. Eur J Cancer 1995; 31A:146\u2013151.","journal-title":"Eur J Cancer"},{"key":"12_CR45","first-page":"135","volume":"102","author":"B Barlogie","year":"2003","unstructured":"Barlogie B, Kyle R, Anderson K, et al. Comparable survival in multiple myeloma (MM) with high dose therapy (HDT) employing MEL 140 mg\/m2 + TBI 12 Gy autotransplants versus standard dose therapy with VBMCP and no benefit from interferon (IFN) maintenance: Results of Intergroup Trial S9321. Blood 2003; 102:Abstract 135.","journal-title":"Blood"},{"key":"12_CR46","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1023\/A:1026548226770","volume":"11","author":"E Fritz","year":"2000","unstructured":"Fritz E, Ludwig H. Interferon-oc treatment in multiple myeloma: meta-analysis of 30 randomized trials among 3,948 patients. Ann Oncol. 2000; 11:1427\u20131436.","journal-title":"Ann Oncol"},{"key":"12_CR47","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1046\/j.1365-2141.2001.02857.x","volume":"113","author":"The Myeloma Trialists\u2019 Collaborative Group","year":"2001","unstructured":"The Myeloma Trialists\u2019 Collaborative Group. Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol. 2001; 113:1020\u20132034.","journal-title":"Br J Haematol"},{"issue":"3","key":"12_CR48","first-page":"12\u2014S17","volume":"34","author":"JM Kirkwood","year":"1998","unstructured":"Kirkwood JM. Systemic adjuvant treatment of high-risk melanoma: the role of interferon alfa-2b and other immunotherapies. Eur J Cancer 1998; 34(suppl 3):S 12\u2014S17.","journal-title":"Eur J Cancer"},{"key":"12_CR49","first-page":"538a","volume":"18","author":"H Zarour","year":"1999","unstructured":"Zarour, H. Richards T, Whiteside J, et al., E2690: intergroup immunological evaluation of IFNoc2b dose-response in patients (Pts) with high-risk melanoma. Proc Am Soc Clin Oncol 1999; 18:538a.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"12_CR50","first-page":"40","volume":"83","author":"M Offidani","year":"1998","unstructured":"Offidani M, Olivieri A, Montillo M, et al. Two dosage interferon -alpha 2b maintenance therapy in patients affected by low-risk multiple myeloma in plateau phase: a randomized trial. Haematologica 1998; 83:40\u201347.","journal-title":"Haematologica"},{"key":"12_CR51","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/j.1600-0609.1996.tb01352.x","volume":"57","author":"K Zervas","year":"1996","unstructured":"Zervas K, Pouli A, Perifanis V, et al. Maintenance therapy with interferon-alpha (IFN-alpha) versus IFN-alpha plus chemotherapy in multiple myeloma (MM). The Greek Myeloma Study Group. Eur J Haematol 1996; 57:142\u2013148.","journal-title":"Eur J Haematol"},{"key":"12_CR52","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1002\/ijc.2910350605","volume":"35","author":"CE Welander","year":"1985","unstructured":"Welander CE, Morgan TM, Homesley HD, Trotta PP, Spiegel RJ. Combined recombinant human interferon alfa 2 and cytotoxic agents studied in a clonogenic assay. Int J Cancer 1985; 35:721\u2013729.","journal-title":"Int J Cancer"},{"key":"12_CR53","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1159\/000204379","volume":"90","author":"A Palumbo","year":"1993","unstructured":"Palumbo A, Boccadoro M, Garino LA, Gallone G, Frieri R, Pileri A. Interferon plus glucocorticoids as intensified maintenance therapy prolongs tumor control in relapsed myeloma. Acta Haematol 1993; 90:71\u201376.","journal-title":"Acta Haematol"},{"key":"12_CR54","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1200\/JCO.1998.16.3.890","volume":"16","author":"SE Salmon","year":"1998","unstructured":"Salmon SE, Crowley JJ, Balcerzak SP, et al. Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group Study. J Clin Oncol 1998; 16:890\u2013896.","journal-title":"J Clin Oncol"},{"issue":"2","key":"12_CR55","first-page":"114","volume":"13","author":"R Powles","year":"1995","unstructured":"Powles R, Raje N, Cunningham D, et al. Maintenance therapy for remission in myeloma with Intron A following high-dose melphalan and either an autologous bone marrow transplantation or peripheral stem cell rescue. Stem Cells 1995; 13(suppl 2): 114\u2013117.","journal-title":"Stem Cells"},{"key":"12_CR56","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1046\/j.1365-2141.1998.00795.x","volume":"102","author":"D Cunningham","year":"1998","unstructured":"Cunningham D, Powles R, Malpas J, et al. A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results. Br J Haematol 1998; 102:495\u2013502.","journal-title":"Br J Haematol"},{"key":"12_CR57","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/sj.bmt.1702826","volume":"27","author":"B Bjorkstrand","year":"2001","unstructured":"Bjorkstrand B, Svensson H, Goldschmidt H, et al. Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2001; 27:511\u2013515.","journal-title":"Bone Marrow Transplant"},{"key":"12_CR58","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/sj.bmt.1701062","volume":"21","author":"A Alegre","year":"1998","unstructured":"Alegre A, Diaz-Mediavilla J, San-Miguel J, et al. Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry. Spanish Registry for Transplant in MM (Grupo Espanol de Transplante Hematopoyetico-GETH) and PETHEMA. Bone Marrow Transplant 1998; 21:133\u2013140.","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"12_CR59","first-page":"132","volume":"13","author":"JL Harousseau","year":"1995","unstructured":"Harousseau JL, Attal M, Divine M, et al. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma. A report of the French Registry on Autologous Transplantation in Multiple Myeloma. Stem Cells 1995; 13(suppl 2): 132\u2013139.","journal-title":"Stem Cells"},{"issue":"1","key":"12_CR60","first-page":"195","volume":"4","author":"B Sirohi","year":"2003","unstructured":"Sirohi B, Powles R, Lawrence D, et al. An open, randomized, controlled, phase II, single centre, 2-period cross over study to compare the quality of life (QoL) and toxicity experienced on PEG interferon (P-IFN) with interferon -alpha2b (IFN) in patients with multiple myeloma (MM) maintained on a steady dose of IFN. 9th International Myeloma Workshop, Salamanca, May 23\u201327, 2003. Hematology J, 4 (suppl 1):S195:242.","journal-title":"Hematology J"},{"key":"12_CR61","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3109\/07357909509024923","volume":"13","author":"AD Valentine","year":"1995","unstructured":"Valentine AD, Meyers CA, Talpaz M. Treatment of neurotoxic side effects of interferon-alpha with naltrexone. Cancer Invest 1995; 13:561\u2013566.","journal-title":"Cancer Invest"},{"key":"12_CR62","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/S0033-3182(95)71658-9","volume":"36","author":"AD Valentine","year":"1995","unstructured":"Valentine AD, Meyers CA. Successful treatment of interferon -alpha-induced mood disorder with nortriptyline. Psychosomatics 1995 36:418\u2013419.","journal-title":"Psychosomatics"},{"issue":"l","key":"12_CR63","first-page":"39","volume":"l","author":"AD Valentine","year":"1998","unstructured":"Valentine AD, Meyers CA, Kling MA, Richelson E, Hauser P. Mood and cognitive side effects of interferon -alpha therapy. Semin Oncol 1998 l(suppl l):39\u201347.","journal-title":"Semin Oncol"},{"key":"12_CR64","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1046\/j.1365-2141.1996.d01-1802.x","volume":"94","author":"F Wisloff","year":"1996","unstructured":"Wisloff F, Hjorth M, Kaasa S, Westin J. Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha interferon. The Nordic Myeloma Study Group. Br J Haematol 1996; 94:324\u2013332.","journal-title":"Br J Haematol"},{"key":"12_CR65","doi-asserted-by":"publisher","first-page":"212","DOI":"10.7326\/0003-4819-124-2-199601150-00004","volume":"124","author":"Nordic Myeloma Study Group","year":"1996","unstructured":"Nordic Myeloma Study Group. Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group. Ann Intern Med 1996; 124:212\u2013222.","journal-title":"Ann Intern Med"},{"key":"12_CR66","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1200\/JCO.1998.16.8.2834","volume":"16","author":"B Zee","year":"1998","unstructured":"Zee B, Cole B, Li T, et al. Quality-adjusted time without symptoms or toxicity analysis of interferon maintenance in multiple myeloma. J Clin Oncol 1998; 16:2834\u20132839.","journal-title":"J Clin Oncol"},{"key":"12_CR67","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1200\/JCO.1997.15.4.1672","volume":"15","author":"H Ludwig","year":"1997","unstructured":"Ludwig H, Fritz E, Neuda J, Durie BG. Patient preferences for interferon alfa in multiple myeloma. J Clin Oncol 1997; 15:1672\u20131679.","journal-title":"J Clin Oncol"},{"key":"12_CR68","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1182\/blood.V99.9.3163","volume":"99","author":"JR Berenson","year":"2002","unstructured":"Berenson JR, Crowley JJ, Grogan TM, et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood 2002; 99:3163\u20133168.","journal-title":"Blood"},{"key":"12_CR69","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","volume":"341","author":"S Singhal","year":"1999","unstructured":"Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma N Engl J Med. 1999; 341:1565\u20131571.","journal-title":"Engl J Med"},{"key":"12_CR70","first-page":"11","volume":"102","author":"S Feyler","year":"2558","unstructured":"Feyler S, Jackson G, Rawstron A, et al. Thalidomide maintenance following high dose therapy in multiple myeloma: a UK Myeloma Forum Phase II Study. American Society of Hematology 45th Annual Meeting, San Diego, Dec. 6\u20139, 2003. Blood 102, 11:2558.","journal-title":"Blood"},{"key":"12_CR71","volume-title":"Thalidomide maintenance following high dose therapy in multiple myeloma: a UK Myeloma Forum Phase 2 Study","author":"S Feyler","year":"2003","unstructured":"Feyler S, Jackson G, Rawstron A, El-Sherbiny YM, Snowden JA, Roderick JJ. Thalidomide maintenance following high dose therapy in multiple myeloma: a UK Myeloma Forum Phase 2 Study. Presented at: the American Society of Hematology 45th Annual Meeting; December 6\u20139, 2003; San Diego, Calif."},{"key":"12_CR72","volume-title":"Feasibility and toxicity of maintenance thalidomide following single cycle autologous peripheral blood stem cell transplant in patients with multiple myeloma","author":"F Sahebi","year":"2003","unstructured":"Sahebi F, Somlo G, Kogut NM, et al. Feasibility and toxicity of maintenance thalidomide following single cycle autologous peripheral blood stem cell transplant in patients with multiple myeloma. Presented at: the American Society of Hematology 45th Annual Meeting; December 6\u20139, 2003; San Diego, Calif. Blood 102, 11:3662."},{"key":"12_CR73","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1093\/annonc\/mdf188","volume":"13","author":"R Alexanian","year":"2002","unstructured":"Alexanian R, Weber D, Giralt S, Delasalle K. Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy. Ann Oncol 2002; 13:1116\u20131119.","journal-title":"Ann Oncol"},{"issue":"1","key":"12_CR74","first-page":"208","volume":"4","author":"AK Stewart","year":"2003","unstructured":"Stewart AK, Chen C, Howson-Jan K, et al. A multi-center randomized phase 2 trial of thalidomide and prednisone as maintenance therapy for multiple myeloma following autologous stem cell transplant. Presented at: the 9th International Myeloma Workshop; May 23\u201327, 2003; Salamanca. Hematol J; 4(suppl 1):S208.","journal-title":"Hematol J"},{"key":"12_CR75","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/j.1365-2141.1991.tb07983.x","volume":"77","author":"HE Heslop","year":"1991","unstructured":"Heslop HE, Duncombe AS, Reittie JE, et al. Interleukin 2 infusion induces haemopoietic growth factors and modifies marrow regeneration after chemotherapy or autologous marrow transplantation. Br J Haematol 1991; 77:237\u2013244.","journal-title":"Br J Haematol"},{"issue":"2","key":"12_CR76","first-page":"72","volume":"13","author":"D Peest","year":"1995","unstructured":"Peest D, Leo R, Deicher H. Tumor-directed cytotoxicity in multiple myeloma: the basis for an experimental treatment approach with interleukin 2. Stem Cells 1995; 13(suppl 2):72\u201376.","journal-title":"Stem Cells"},{"key":"12_CR77","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/j.1365-2141.1990.tb07789.x","volume":"75","author":"DJ Gottlieb","year":"1990","unstructured":"Gottlieb DJ, Prentice HG, Mehta AB, et al. Malignant plasma cells are sensitive to LAK cell lysis: pre-clinical and clinical studies of interleukin 2 in the treatment of multiple myeloma. Br J Haematol 1990; 75:499\u2013505.","journal-title":"Br J Haematol"},{"key":"12_CR78","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1182\/blood.V74.4.1374.1374","volume":"74","author":"HE Heslop","year":"1989","unstructured":"Heslop HE, Gottlieb DJ, Bianchi AC, et al. In vivo induction of gamma interferon and tumor necrosis factor by interleukin-2 infusion following intensive chemotherapy or autologous marrow transplantation. Blood 1989; 74:1374\u20131380.","journal-title":"Blood"},{"key":"12_CR79","first-page":"650","volume":"30","author":"A Togawa","year":"1989","unstructured":"Togawa A, Sawada S, Amano M, Oshimi K, Satoh H, Takaku H. Treatment of multiple myeloma with LAK cells plus interleukin 2 or interleukin 2 alone [article in Japanese]. Rinsho Ketsueki 1989; 30:650\u2013658.","journal-title":"Rinsho Ketsueki"},{"key":"12_CR80","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/sj.bmt.1700687","volume":"19","author":"N Robinson","year":"1997","unstructured":"Robinson N, Benyunes MC, Thompson JA, et al. Interleukin-2 after autologous stem cell transplantation for hematologic malignancy: a phase I\/II study. Bone Marrow Transplant 1997; 19:435\u2013442.","journal-title":"Bone Marrow Transplant"},{"key":"12_CR81","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1182\/blood.V77.12.2561.2561","volume":"77","author":"CM Higuchi","year":"1991","unstructured":"Higuchi CM, Thompson JA, Petersen FB, Buckner CD, Fefer A. Toxicity and immunomodulatory effects of interleukin-2 after autologous bone marrow transplantation for hematologic malignancies. Blood 1991; 77:2561\u20132568.","journal-title":"Blood"},{"key":"12_CR82","unstructured":"Peest D, Hannover, Germany. Personal communication."},{"key":"12_CR83","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1056\/NEJMoa030288","volume":"348","author":"PG Richardson","year":"2003","unstructured":"Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003; 348:2609\u20132617.","journal-title":"N Engl J Med"},{"key":"12_CR84","first-page":"211","volume":"47","author":"H Mellstedt","year":"1999","unstructured":"Mellstedt H, Osterborg A. Active idiotype vaccination in multiple myeloma: GM-CSF may be an important adjuvant cytokine. Pathol Biol (Paris) 1999; 47:211\u2013215.","journal-title":"Pathol Biol (Paris)"},{"key":"12_CR85","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJM199210223271705","volume":"327","author":"LW Kwak","year":"1992","unstructured":"Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 1992; 327:1209\u20131215.","journal-title":"N Engl J Med"},{"key":"12_CR86","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1089\/hum.1998.9.8-1121","volume":"9","author":"JG Turner","year":"1998","unstructured":"Turner JG, Tan J, Crucian BE, et al. Broadened clinical utility of gene gun-mediated, granulocyte-macrophage colony-stimulating factor cDNA-based tumor cell vaccines as demonstrated with a mouse myeloma model. Hum Gene Ther 1998; 9:1121\u20131130.","journal-title":"Hum Gene Ther"},{"key":"12_CR87","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1182\/blood.V93.7.2411","volume":"93","author":"VL Reichardt","year":"1999","unstructured":"Reichardt VL, Okada CY, Liso A, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma: a feasibility study. Blood 1999; 93:2411\u20132419.","journal-title":"Blood"},{"key":"12_CR88","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/j.1600-065X.1995.tb00083.x","volume":"145","author":"FK Stevenson","year":"1995","unstructured":"Stevenson FK, Zhu D, King CA, Ashworth LJ, Kumar S, Hawkins RE. Idiotypic DNA vaccines against B-cell lymphoma. Immunol Rev 1995; 145:211\u2013128.","journal-title":"Immunol Rev"},{"issue":"3","key":"12_CR89","first-page":"30","volume":"36","author":"DG Maloney","year":"1999","unstructured":"Maloney DG, Donovan K, Hamblin TJ. Antibody therapy for treatment of multiple myeloma. Semin Hematol 1999; 36(suppl 3):30\u201333.","journal-title":"Semin Hematol"},{"key":"12_CR90","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/S0025-6196(12)61350-0","volume":"69","author":"GJ Ruiz-Arguelles","year":"1994","unstructured":"Ruiz-Arguelles GJ, San Miguel JF. Cell surface markers in multiple myeloma. Mayo Clin Proc 1994; 69:684\u2013690.","journal-title":"Mayo Clin Proc"},{"key":"12_CR91","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1097\/00002371-200201000-00008","volume":"25","author":"SP Treon","year":"2002","unstructured":"Treon SP, Pilarski LM, Belch AR, et al. CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. J Immunother. 2002; 25:72\u201381.","journal-title":"J Immunother"},{"key":"12_CR92","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1046\/j.1365-2141.2003.04675.x","volume":"123","author":"P Musto","year":"2003","unstructured":"Musto P, Carella AM Jr, Greco MM, et al. Short progression-free survival in myeloma patients receiving rituximab as maintenance therapy after autologous transplantation. Br J Haematol. 2003; 123:746\u2013747.","journal-title":"Br J Haematol"},{"key":"12_CR93","doi-asserted-by":"crossref","first-page":"551","DOI":"10.3109\/10428199809057614","volume":"31","author":"HC Zaanen Van","year":"1998","unstructured":"Van Zaanen HC, Lokhorst HM, Aarden LA, Rensink HJ, Warnaar SO, Van Oers MH. Blocking interleukin-6 activity with chimeric anti-IL6 monoclonal antibodies in multiple myeloma: effects on soluble IL6 receptor and soluble gpl30. Leuk Lymphoma 1998; 31:551\u2013558.","journal-title":"Leuk Lymphoma"},{"key":"12_CR94","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/sj.leu.2402081","volume":"15","author":"F Garban","year":"2001","unstructured":"Garban F, Attal M, Rossi JF, Payen C, Fegueux N, Sotto JJ: Intergroupe Francophone du Myelome. Immunotherapy by nonmyeloablative allogeneic stem cell transplantation in multiple myeloma: results of a pilot study as salvage therapy after autologous transplantation. Leukemia. 2001; 15:642\u2013646.","journal-title":"Leukemia"},{"key":"12_CR95","doi-asserted-by":"crossref","unstructured":"Bethge WA, Hegenbart U, Stuart MJ, et al. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Blood 2003, [Epub ahead of print].","DOI":"10.1182\/blood-2003-07-2344"},{"key":"12_CR96","first-page":"139","volume":"102","author":"R Vij","year":"2003","unstructured":"Vij R, Borrello IM, Martin T, et al. A phase I\/II study of Xcellerated T cells(tm) after autologous peripheral blood stem cell transplantation in patients with multiple myeloma. Presented at: the American Society of Hematology 45th Annual Meeting; Dec. 6\u20139, 2003; San Diego, Calif. Blood 102,11:139.","journal-title":"Blood"},{"issue":"1","key":"12_CR97","first-page":"11","volume":"4","author":"PR Greipp","year":"2003","unstructured":"Greipp PR, Vesole D, Rajkumar SV, Kyle RA. Use of Zoledronic acid in early stage disease, MGUS and indolent myeloma. Presented at: the 9th International Workshop on Multiple Myeloma; May 23\u201327, 2003; Salamanca. Hematol J; 4(suppl 1):S11.","journal-title":"Hematol J"},{"key":"12_CR98","doi-asserted-by":"publisher","first-page":"3719","DOI":"10.1200\/JCO.2002.06.037","volume":"20","author":"JR Berenson","year":"2002","unstructured":"Berenson JR, Hillner BE, Kyle RA, et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2002; 20:3719\u20133736.","journal-title":"J Clin Oncol"}],"container-title":["Biology and Management of Multiple Myeloma"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-59259-817-5_12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T20:57:40Z","timestamp":1715461060000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-59259-817-5_12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004]]},"ISBN":["9781617371431","9781592598175"],"references-count":98,"URL":"https:\/\/doi.org\/10.1007\/978-1-59259-817-5_12","relation":{"is-part-of":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1007\/978-1-59259-817-5","asserted-by":"object"}]},"subject":[],"published":{"date-parts":[[2004]]}}}